Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%)
Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic distributors to 41% and grew revenue per surgery by 15% (17% in 3Q19) as surgeon adoption of products increases
Products launched within the quarter include IdentiTi ALIF, InVictus MIS Single-Step, InVictus Open and IdentiTi TLIF-PO
Leadership is excited about the clinical distinction that will be created by the November 2019 full launch of SafeOp, the neuromonitoring component of the Alpha InformatiX platform, and expects it to be a key factor in selling entire surgical approaches with an associated increase of products sold per surgery
ORTHOWORLD projects Alphatec full year 2019 revenue of $110.6MM, +20.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
3Q19
3Q18
$ Chg
% Chg
Spine
$26.7
$21.0
$5.7
27%
Orthobiologics
$2.5
$2.0
$0.5
26.2%
Total
$29.2
$23.0
$6.2
26.9%
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$74.0
$60.3
$13.7
22.6%
Orthobiologics
$7.1
$6.0
$1.1
18.7%
Total
$81.1
$66.3
$14.8
22.3%
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
3Q19
3Q18
$ Chg
% Chg
US
$28.1
$21.0
$7.1
33.6%
Ex-US
$1.2
$2.0
($0.9)
(42.7%)
Total
$29.2
$23.0
$6.2
26.9%
Net earnings are as follows ($MM).
Amt
% of Sales
Sales
$29.2
Cost of Sales
($9.3)
31.7%
Selling and Admin
($26.8)
91.8%
R & D
($4.0)
13.6%
Other
($0.8)
2.7%
Net Earnings
($11.6)
(39.7%)
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%) Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic...
Alphatec updated 2019 full year revenue guidance to the range of $109MM (+19%) to $112MM (+22%)
Year to date the company has launched 11 new products (four in 3Q19), expanded revenue contribution from new products to 33%, drove revenue growth from strategic distributors to 41% and grew revenue per surgery by 15% (17% in 3Q19) as surgeon adoption of products increases
Products launched within the quarter include IdentiTi ALIF, InVictus MIS Single-Step, InVictus Open and IdentiTi TLIF-PO
Leadership is excited about the clinical distinction that will be created by the November 2019 full launch of SafeOp, the neuromonitoring component of the Alpha InformatiX platform, and expects it to be a key factor in selling entire surgical approaches with an associated increase of products sold per surgery
ORTHOWORLD projects Alphatec full year 2019 revenue of $110.6MM, +20.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
3Q19
3Q18
$ Chg
% Chg
Spine
$26.7
$21.0
$5.7
27%
Orthobiologics
$2.5
$2.0
$0.5
26.2%
Total
$29.2
$23.0
$6.2
26.9%
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$74.0
$60.3
$13.7
22.6%
Orthobiologics
$7.1
$6.0
$1.1
18.7%
Total
$81.1
$66.3
$14.8
22.3%
ORTHOWORLD estimates orthopedic sales by geographic region as follows ($MM).
3Q19
3Q18
$ Chg
% Chg
US
$28.1
$21.0
$7.1
33.6%
Ex-US
$1.2
$2.0
($0.9)
(42.7%)
Total
$29.2
$23.0
$6.2
26.9%
Net earnings are as follows ($MM).
Amt
% of Sales
Sales
$29.2
Cost of Sales
($9.3)
31.7%
Selling and Admin
($26.8)
91.8%
R & D
($4.0)
13.6%
Other
($0.8)
2.7%
Net Earnings
($11.6)
(39.7%)
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
